Radiotherapy Extends Life for Advanced Lung Cancer Patients, Study Shows

Doctors have announced a significant advancement in treating advanced lung cancer, as new research suggests that incorporating radiotherapy into standard treatment regimens can extend the time patients live without their disease worsening. The findings offer renewed hope for individuals diagnosed with non-small cell lung cancer (NSCLC), a form of the disease with historically low survival rates.

Advanced lung cancer is characterized by a five-year survival rate of only 15 percent. However, the recent study indicates that adding high-dose radiotherapy to conventional chemotherapy or immunotherapy can lead to a 56 percent improvement in progression-free survival. Patients receiving the combined treatment lived an average of 13.9 months without their cancer progressing, compared to eight months for those on standard treatment alone.

Experts presented the results at the European Society of Medical Oncology’s (ESMO) annual meeting in Madrid, describing the findings as a 'crucial' turning point and suggesting the 'landscape is now changing for cancer patients.'

Trial Details and Findings

The SARON trial, a collaborative study involving 140 patients across 19 UK centers, focused on patients with advanced NSCLC that had spread to up to three organs. Half of the participants received standard chemotherapy or immunotherapy, while the other half received the same standard treatment augmented with localized radiotherapy targeted at all known sites of the disease, including the primary tumor, nearby lymph nodes, and secondary tumors.

During the year following treatment, only 13 percent of patients who received radiotherapy experienced tumor growth, a significant reduction compared to 40 percent of patients on standard care. Importantly, the radiotherapy was well-tolerated and did not negatively impact patients' quality of life.

Dr. Fiona McDonald, consultant oncologist at The Royal Marsden and chief investigator of the trial, stated that the study provides 'important data' demonstrating a 'significant improvement in progression-free survival without compromising quality of life.' She advised that doctors should discuss radiotherapy as an option with eligible patients.

Cancer Research UK also welcomed the findings, with Dr. Dani Skirrow, the charity's science engagement manager, emphasizing the value of 'precious time' for patients and their loved ones. 'Being able to keep the disease stable matters enormously, helping people to live a better quality of life,' Skirrow said.

Patient Experience

One patient, 69-year-old Julie Moran from Buckinghamshire, shared her positive experience. Diagnosed with advanced lung cancer in 2020 after a persistent cough, she was enrolled in the trial. Six years later, her disease remains stable following immunotherapy and radiotherapy.

Moran, a former cardiac technician, noted that her symptoms might have gone unnoticed without a COVID-19-related scan. She expressed gratitude for the treatment's effectiveness, which has allowed her to return to work and spend time with her family. Annually, approximately 44,000 people in the UK are diagnosed with non-small cell lung cancer, with about a fifth of those diagnosed at a stage where the cancer has already spread beyond the lungs.